Fingolimod was the first S1PR modulator to gain regulatory approval for the treatment of relapsing-remitting MS (RRMS), which has broad receptor affinity for S1PR1, 3, 4, and 5. The gene discussed is S1PR1; the disease is relapsing-remitting multiple sclerosis.